随着烟台迈百瑞国际生物医药股份有限公司(以下简称“迈百瑞”)创业板IPO撤单,上海建发致新医疗科技集团股份有限公司(以下简称“建发致新”)成为目前深市闯关IPO的唯一一家医药企业。今年以来,已有多家医药企业IPO撤单,其中多家企业已走到注册阶段。“独苗”建发致新目前处于上市委会议通过阶段,等待提交注册。而在上会阶段,建发致新曾遭暂缓审议。年内深市5家药企IPO撤单今年以来,深市已有5家药企IPO...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.